top of page
Jun 17, 20225 min read

EASL's International Liver Congress (ILC) 2022 - Clinical Presentations

Updated: Jun 27, 2022

Updated 6/27/22


Summary

  • The International Liver Congress (ILC) 2022 is taking place from June 22 - 26 in-person at ExCeL in London and sessions are available online

  • More than 400 sessions will be available in person and online, focusing on hepatology

  • #ILC2022 will feature presentations on immune mediated diseases, liver tumors, cirrhosis, and more

  • See our full forum post for more in depth info on data being presented

  • Updated 6.21.22 to add three additional companies

  • Updated 6.27.22 to include top positive and negative moves during congress


The European Association for the Study of the Liver’s (EASL) annual liver conference - the International Liver Congress 2022 (ILC) is taking place virtually and in person in London from June 22-26, 2022. This congress will feature over 400 presentations that focus on liver disease, liver tumors, general hepatology, and more. “ILC 2022 will offer the highest-quality arena to present and discuss the latest scientific achievements, the best school to adjourn young hepatologists on clinical practice, and the largest platform for person-to-person interaction and social exchange.” (https://easl.eu/event/international-liver-congress-2022/welcome-message/).




 

Want to get Catalyst Events and stocks to watch sent directly to your inbox each week? sign up for our free weekly newsletter

 

Abstracts for regular ILC 2022 oral presentations and poster sessions were released on June 8, 2022. Accepted abstracts in General Session I, General Session II, and the Late Breaker Session will not be disclosed until the start time of the press conference when the abstract is featured. Data from late breaker abstracts presenting with posters cannot be disclosed until the start of ILC 2022: Wednesday June 22 at 8am BST. June 22 and specific session times throughout the week are then important dates when more data may be presented from these abstracts.


There are 13 smid-cap biopharma companies in the BPIQ database that are presenting clinical data at ILC 2022. Several of these companies have multiple presentations (oral or poster) during the week of ILC and will include updates to ongoing /future trials.


Every year, upon abstract release and as a result of presentations at the conference, some biopharma stocks move significantly because they report important clinical trial updates. As experienced biopharma investors understand, the value of a biopharma company is based in large part on the value of its clinical assets. This value takes into account the likelihood of success of the clinical assets of the underlying company in successfully completing clinical trials. An update to a clinical trial that shows some positive results in safety and especially efficacy, can increase the chance of success for that trial, which increases the value of the asset and the underlying company. The converse is true as well, for disappointing results.


Positive clinical trial results in a single trial can have a significant impact on the underlying stock price. This is especially true for biopharma companies with market caps under $5 billion, who typically have far less clinical and approved assets than larger companies, and thus whose valuation can be more affected by a single drug candidate and trial. The clinical assets of these micro, small and mid-cap cancer biopharma companies are a primary driver for the development of future cancer therapies.


With respect to ILC 2022, and biomedical conferences in general, a big challenge for investors is to identify in advance, companies that are reporting significant clinical trial updates at the conference. Many presentations provide less significant information with respect to company valuation (e.g. preclinical results or clinical trial design). At BiopharmIQ (BPIQ.com; "BPIQ") we oversee a database of information about clinical assets and their upcoming clinical trial and other catalyst events for virtually every biopharma company with a market cap of between $100M and $5B, which for convenience in this article, we will refer to as smid-cap biopharma companies. Currently, our database has over 550 smid-cap biopharma companies. Our goal at BPIQ is to provide information and education on smid-CAP biopharma companies to level the playing field for all investors, whether retail, professional or institutional.


To this end, our team updated and scoured through our BPIQ database to identify biopharma companies that are presenting at these upcoming conferences and if new data will be provided. Table 1 lists those companies in our BPIQ database that are presenting at ILC 2022. This table provides the drug candidate name, indication, and phase of data to be presented. Also included in this table are links to press releases and IQ cards. See our forum for more info regarding data to be presented.


The question for biopharma investors now with respect to the actual ILC meeting is which stocks or groups of stocks are likely to move upon the release of the abstracts, posters, or associated investor meeting. Abstracts were released June 8, but starting on the first day of the congress (June 22) late breaking abstracts and presentations will be released, with more data coming during presentation times. These could then be important days for investors to watch for stock moves. We plan to update information about the presentations on BPIQ.com as they become available. In the meantime, the information provided in this article provides an interesting snapshot into the smid-cap biopharma companies that are developing some of the leading medicines for multiple sclerosis and kidney diseases. For investors, these companies represent an exciting opportunity for further diligence and possible investment.


See our forum for more information on these companies presenting clinical trial data.


Table 1. #ILC2022 BPIQ smid-cap companies presenting clinical trials



See our full forum post for more info on these companies including data being presented, and investor calls



Updated 6/27/2022

ILC concluded yesterday (Sunday 6/26/22), and many smid-cap biopharmas saw large stock moves over the weekend. Table 2 shows the top five positive moves and Table 3 shows the top five negative moves from smid-cap companies that presented at ILC (stock moves from 6/21 to 6/27). See our full forum post for all of the company moves during the days of the congress.



Table 2. Top ILC moves (top 5 positive moves from 6/22-6/26)



Table 3. Top ILC moves (top 5 negative moves from 6/22-6/26)




This article is NOT legal, investment or tax advice. Please do your own diligence before making any investments.



 

If you are serious about investing in biotech stocks BPIQ is the research companion that will take you to the next level.


Save yourself time by accessing our database of over 550 companies, 1,800+ of their drug assets, and tools including: Catalyst Calendar, Big Movers, Company Pipelines, and more!

P.S. We are currently running a sale - lock in the price before it's gone

 

See what our members are saying about us:


Mike from United States

“Really loving the site over the competitor... like the layout and speed over the competition...like the individual pages for each drug/treatment”

Carl from United States

“I like your service. I haven’t seen anyone else doing something similar...nothing like this available for retail.”

Essey from Canada

“Love what you’re doing, this website is awesome.”

James from United States

Great site and I see it’s a family run business, great job.”

0 comments

Comments

bottom of page